Yang Q, Zhang H, Ma PQ, Peng B, Yin GT, Zhang NN, Wang HB. Value of ultrasound and magnetic resonance imaging combined with tumor markers in the diagnosis of ovarian tumors. World J Clin Cases 2023; 11(31): 7553-7561 [PMID: 38078133 DOI: 10.12998/wjcc.v11.i31.7553]
Corresponding Author of This Article
Hai-Bao Wang, MD, PhD, Chief Physician, Professor, The First Affiliated Hospital of Anhui Medical University, No. 218 Jixi Road, Hefei 230022, Anhui Province, China. wang23415@126.com
Research Domain of This Article
Oncology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Nov 6, 2023; 11(31): 7553-7561 Published online Nov 6, 2023. doi: 10.12998/wjcc.v11.i31.7553
Value of ultrasound and magnetic resonance imaging combined with tumor markers in the diagnosis of ovarian tumors
Qian Yang, Hui Zhang, Pei-Qi Ma, Bin Peng, Gui-Tao Yin, Nan-Nan Zhang, Hai-Bao Wang
Qian Yang, Hui Zhang, Hai-Bao Wang, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, Anhui Province, China
Qian Yang, Taihe Hospital of Traditional Chinese Medicine, Fuyang 236000, Anhui Province, China
Pei-Qi Ma, Bin Peng, Fuyang People’s Hospital, Fuyang 236000, Anhui Province, China
Gui-Tao Yin, No. 2 People’s Hospital of Fuyang City, Fuyang 236000, Anhui Province, China
Nan-Nan Zhang, Linquan People’s Hospital, Fuyang 236000, Anhui Province, China
Author contributions: Yang Q and Zhang H contributed to the conceptualization of this study; Ma PQ, Peng B, Yin GT involved in the methodology of the manuscript; Zhang NN took part in the formal analysis; Wang HB contributed to the investigation; Yang Q prepared the original draft; Wang HB involved in the writing-review and editing, and supervision; and all authors have read and agreed to the published version of the manuscript.
Institutional review board statement: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of the First Affiliated Hospital of Anhui Medical University.
Informed consent statement: The informed consent was obtained from all patients before specimen collection.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hai-Bao Wang, MD, PhD, Chief Physician, Professor, The First Affiliated Hospital of Anhui Medical University, No. 218 Jixi Road, Hefei 230022, Anhui Province, China. wang23415@126.com
Received: August 23, 2023 Peer-review started: August 23, 2023 First decision: September 13, 2023 Revised: September 21, 2023 Accepted: October 25, 2023 Article in press: October 25, 2023 Published online: November 6, 2023
ARTICLE HIGHLIGHTS
Research background
Ultrasound (US), magnetic resonance imaging (MRI), and serum tumor marker detection are currently effective clinical tools for diagnosing ovarian cancer. However, there are currently limited studies that investigate their individual or combined use for detection.
Research motivation
This study aimed to investigate the diagnostic value of US, MRI, and tumor marker detection alone or in combination for ovarian tumors.
Research objectives
Comprehensive comparison of US, MRI combined with tumor markers in the diagnosis of ovarian tumors.
Research methods
A total of 110 ovarian cancer patients were selected as research subjects from our hospital, spanning from February 2018 to May 2023. These patients were confirmed to have ovarian cancer through surgery and pathology, with 60 cases being benign tumors and 50 cases being malignant tumors. Prior to surgery, all patients underwent preoperative US and MRI examinations, along with serum tumor marker testing for carbohydrate antigen 125 (CA125) and human epididymis protein 4 (HE4).
Research results
This study investigated the differences in ultrasound imaging characteristics between benign and malignant tumors. The study found that there were statistically significant differences in echogenic characteristics, presence or absence of capsule, blood flow resistance index, clear tumor shape, and blood flow signal display rate (P < 0.05). The apparent diffusion coefficient values of the solid and cystic parts of benign tumors were observed to be higher than those of malignant tumors (P < 0.05). Moreover, significant statistical differences were found in the time-intensity curve image features of benign and malignant tumors (P < 0.05). The levels of serum CA125 and HE4 were found to be lower in benign tumors compared to malignant tumors (P < 0.05). The combined use of ultrasound, MRI, and tumor markers resulted in higher accuracy, sensitivity, and specificity in diagnosing ovarian tumors than using each method alone (P < 0.05).
Research conclusions
The use of US, MRI, and tumor markers in diagnosing ovarian tumors has both advantages and disadvantages. However, combining these three methods can greatly enhance the accuracy of diagnosis, facilitate early detection, identify the nature of the tumor, and offer valuable guidance for clinical treatment.
Research perspectives
The early detection and targeted treatment are crucial for improving the prognosis of patients with ovarian tumors.
